share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  06/26 08:33

Moomoo AI 已提取核心訊息

On June 26, 2024, Aclarion, Inc., a healthcare technology company, announced that its Nociscan product has secured initial payer coverage by AXA, a major private medical insurance provider in the U.K., specifically for the greater London area. This coverage by AXA, which is the second-largest provider of private medical insurance in the U.K., represents a significant milestone for Aclarion as it is the first insurance company to approve payment for Nociscan. The London Clinic, a prominent independent hospital in the U.K., has adopted Nociscan as a decision support tool for diagnosing and treating chronic low back pain patients. The AXA coverage decision is expected to increase access to Nociscan for insured patients, marking a crucial step in Aclarion's commercialization efforts and potentially leading to wider adoption as other insurers may follow AXA's lead. Aclarion leverages Magnetic Resonance Spectroscopy and proprietary algorithms to help physicians identify the sources of chronic low back pain, aiming to improve treatment outcomes.
On June 26, 2024, Aclarion, Inc., a healthcare technology company, announced that its Nociscan product has secured initial payer coverage by AXA, a major private medical insurance provider in the U.K., specifically for the greater London area. This coverage by AXA, which is the second-largest provider of private medical insurance in the U.K., represents a significant milestone for Aclarion as it is the first insurance company to approve payment for Nociscan. The London Clinic, a prominent independent hospital in the U.K., has adopted Nociscan as a decision support tool for diagnosing and treating chronic low back pain patients. The AXA coverage decision is expected to increase access to Nociscan for insured patients, marking a crucial step in Aclarion's commercialization efforts and potentially leading to wider adoption as other insurers may follow AXA's lead. Aclarion leverages Magnetic Resonance Spectroscopy and proprietary algorithms to help physicians identify the sources of chronic low back pain, aiming to improve treatment outcomes.
2024年6月26日，醫療科技公司Aclarion宣佈其Nociscan產品已獲得英國主要私人醫療保險提供商之一AXA的初步支付者覆蓋範圍，特別是針對倫敦地區。AXA是英國第二大私人醫療保險提供商，此次覆蓋是Aclarion的一個重要里程碑，因爲它是第一家批准Nociscan付款的保險公司。英國著名的獨立醫院倫敦診所已將Nociscan作爲診斷和治療慢性低背痛患者的決策支持工具。AXA的覆蓋決定有望增加已保險患者對Nociscan的使用，標誌着Aclarion商業化努力的關鍵一步，可能會導致其他保險公司跟隨AXA的步伐，進一步擴大Nociscan的採用。Aclarion利用磁共振波譜和專有算法幫助醫生確定慢性低背痛的源頭，旨在改善治療結果。
2024年6月26日，醫療科技公司Aclarion宣佈其Nociscan產品已獲得英國主要私人醫療保險提供商之一AXA的初步支付者覆蓋範圍，特別是針對倫敦地區。AXA是英國第二大私人醫療保險提供商，此次覆蓋是Aclarion的一個重要里程碑，因爲它是第一家批准Nociscan付款的保險公司。英國著名的獨立醫院倫敦診所已將Nociscan作爲診斷和治療慢性低背痛患者的決策支持工具。AXA的覆蓋決定有望增加已保險患者對Nociscan的使用，標誌着Aclarion商業化努力的關鍵一步，可能會導致其他保險公司跟隨AXA的步伐，進一步擴大Nociscan的採用。Aclarion利用磁共振波譜和專有算法幫助醫生確定慢性低背痛的源頭，旨在改善治療結果。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間